Mazdak Ganjalikhani-Hakemi PhD (Isfahan University of Medical Sciences)
Associate professor/Sinior researched, Istanbul Medipol University, Istanbul · Turkey
Editorial leadership for Journal of Hematology and Oncology Research ISSN 2372-6601
Research interests
- Cancer Immunotherapy Rnai Immunology
Biography
Dr. Mazdak Ganjalikhani-Hakemi is an Associate Professor and Senior Researcher at Istanbul Medipol University in Istanbul, Turkey, having completed his PhD at Isfahan University of Medical Sciences. His research focuses on immunology, particularly the roles of T helper cell subsets (Th17, Treg) and innate lymphoid cells in chronic inflammatory and autoimmune conditions, including periodontal disease, asthma, multiple sclerosis, ankylosing spondylitis, and primary immunodeficiencies such as common variable immunodeficiency. He has authored over 20 indexed publications, with his most-cited work, "Mesenchymal Stem Cell-Derived Extracellular Vesicles: A Novel Cell-Free Therapy" (2020), receiving 96 citations. His contributions span cellular immunology, cytokine biology, and the genetic and molecular mechanisms underlying immune dysregulation.
Selected publications
- Mesenchymal Stem Cell-Derived Extracellular Vesicles: A Novel Cell-Free Therapy 2020 cited 96×
- mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients 2021 cited 88×
- Therapeutic effects of extracellular vesicles from human adipose‐derived mesenchymal stem cells on chronic experimental autoimmune encephalomyelitis 2020 cited 78×
- Analysis of the expression of mir-34a, mir-199a, mir-30c and mir-19a in peripheral blood CD4+T lymphocytes of relapsing-remitting multiple sclerosis patients 2018 cited 50×
- Quercetin potential effects against SARS‐CoV‐2 infection and COVID‐19‐associated cancer progression by inhibiting mTOR and hypoxia‐inducible factor‐1α (HIF‐1α) 2022 cited 36×
- Flt3-ITD mutated acute myeloid leukemia patients and COVID-19: potential roles of autophagy and HIF-1α in leukemia progression and mortality 2022 cited 16×
Ranked by citation impact (Crossref) where available, newest otherwise · verified via ORCID.
Considering JHOR for your work?
This journal is guided by Mazdak Ganjalikhani-Hakemi (Associate professor/Sinior researched, Istanbul Medipol University, Istanbul) and a peer-review board of practising researchers. Open access, author-retained copyright (CC BY), and a clear editorial process.